Our vision

A world without MS

soliris NMOSD

NMOSD medication not recommended for the PBS for a second time

Soliris® (eculizumab), the first TGA-approved medication for NMOSD, has not been recommended for listing on the PBS.

ATA188: Improvements in progressive MS maintained in extension of initial trials

New imaging data shows sustained improvement in disability and increases in myelin density in the brain following an experimental treatment for progressive MS.
rohan greenland

A note from our CEO: Rohan Greenland – December

CEO Rohan Greenland gives an update on the MS Australia activities for December, focusing on the year ahead for MS Australia.
The May 50K 2021

Thank you for raising over $5.3 million for MS research in 2021

We look back on the enormous milestones reached in 2021 thanks to the Kiss Goodbye to MS community. Thank you for continuing to accelerate our superpower – MS research.
NDIS support

Does NDIS support match the level of disability needs for people with MS?

A recent study from regional NSW is the first to assess if the NDIS package allocated to people with MS matches the level of disability measured by a formal neurological assessment. 
myelin cell neuron

What drives myelin damage in MS?

A new study of brain tissue has found that immune cells derived from blood immune cells, attack myelin in the very early stages of MS.
Read More

Newsletter subscription

  • Enter your details